AU667611B2 - Syrup containing N-acetyl-cysteine - Google Patents
Syrup containing N-acetyl-cysteineInfo
- Publication number
- AU667611B2 AU667611B2 AU56266/94A AU5626694A AU667611B2 AU 667611 B2 AU667611 B2 AU 667611B2 AU 56266/94 A AU56266/94 A AU 56266/94A AU 5626694 A AU5626694 A AU 5626694A AU 667611 B2 AU667611 B2 AU 667611B2
- Authority
- AU
- Australia
- Prior art keywords
- nac
- syrup
- sodium
- solution
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Jellies, Jams, And Syrups (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Description
SYRUP CONTAINING N-ACETYL-CYSTEINE The present invention relates to a composition in the form of a syrup containing N-acetyl-cysteine as active ingredient .
N-acetyl-cysteine (hereinafter briefly referred to as NAC) is a compound endowed with several useful pharmacological properties, making it a widely used drug. •
In the treatment of cold diseases, NAC showed to be useful thanks TO its mucolytic properties.
One of the pharmaceutical forms largely used in the therapy of cold diseases is syrup, particularly suitable also for pediatric use.
NAC is available in several pharmaceutical forms, however the high reactivity of the molecule, the relative instability and the characteristic sulphureous smell and taste make extremely troublesome the achievement of liquid forms for oral use which are time-stable and with a good palatability.
The preparation of a syrup provides, practically in ail the cases, the use of a disaccharide (sucrose) or of a simple sugar as a sweetening and thickening agent of the aqueous solution of the drug. However, the interaction of NAC with sugars gives to the solution an unacceptable brown colouring and the titre of NAC decreases.
Thus, it is not possible to leave NAC in solution for a long time in the presence of sucrose.
Similarly, the reactions giving brown colour and causing bad smell take place also between NAC and the monosaccharides whose use is described in the French patent application No. 2631831 in the name of Calco Anstalt.
As far as we know, the only syrup formulation containing NAC on the market consists in a composition to be prepared at the moment of use by dissolution in water of a granulate. After preparation, the extemporaneous syrup must be used within 3
weeks.
We have now surprisingly found that it is possible to prepare a time-stable NAC syrup having a pleasant taste without using sugars.
Therefore, object of the present invention is a composition in the form of a syrup containing (each 100 ml) :
- N-acetyl-cysteine 2 -4.2 g/100 ml
- a sweetening agent 0.02-0.3 g/100 ml
- a thickening agent selected among: sodium carboxymethylcellulose and hydroxypropylmethylcellulose or mixtures thereof 0.1 -A g/100 mi and optionally:
- a flavouring agent 0.1 -0.4 g/100 ml - a preservative 0.05-0.5 g/100 ml and further
- water q.s. to 100 ml pH being settled within the interval 5-8.
The above solution results to be stable in a closed bottle under inert gas for at least 2 years under environmental conditions. When the bottle is opened, the solution shows to have a pleasant taste and to be free from bad smells; NAC maintains the initial titre and the open syrup results to be stable for at least 5 weeks.
For sweetening agent we mean a substance able to give a sweet taste to the solution but wich does not contain sugars. Specific examples of sweetening agents are saccharin, sodium saccharin and cyclamates or mixtures thereof.
The amount of sweetening agent will be the minimum amount sufficient to give a pleasant taste to the solution. The thickening agent is selected among sodium carboxymethylcellulose
methylcellulose and hydroxypropylmethylcellulose or mixtures thereof. Surprisingly, these substances showed to be compatible with
NAC and to be able to give to the solution a thickness suitable for ς the usual palatability of a syrup.
To these three base components (NAC, sweetening agent and thickening agent) water can be added up to the selected volume, by optionally rectifying the resultant pH so that it is maintained within the interval from 5 to 8. Preferably, pH will be from 6.5 to 7. The syrup could also, but not necessarily, contain a flavouring agent in order to improve the palatability, especially for pediatric use.
Since the syrup is generally manufactured in absence of asepsis, phar acopoeiae require the compulsory presence of a preservative. The preservative is further required to assure the microbiological quality during the time of use by the patient.
In this case, preservatives selected among sodium benzoate, methyl • -hydroxybenzoate, propyl •.-hydroxybenzoate and mixtures thereof will be preferably used. With the double function of preservative and of metal chelating agent also sodium EDTA could be used in addition to or in partial substitution of the above preservatives.
The preparation of the syrup according to the present invention is carried out under inert gas by simple dissolution of the substances in the predetermined amount of water.
The resultant solution is shared into multidose bottles or in single-dose containers.
The packaging of multi-dose bottles could provide the contemporaneous supplying of a graduated measure for the correct dosage of the single doses for grown-up people (for example 10 ml) or for children
- A -
( for example 5 ml ) .
In order to better illustrate the present invention the following examples are now given. ς
Example 1
10 liters of a syrup containing (each 100 ml):
NAC 2.1 g
Saccharin 0.04 g
Sodium carboxymethylcellulose 0.2 g Sodium benzoate 0.15 g
Sodium edetate 0.1 g
Raspberry flavour 0.25 g
Water q.s. to 100 ml were prepared by simple dissolution of the substances in purified and de-aerated water under nitrogen atmosphere.
The pH of the resultant solution was rectified to the correct value
6.5 by addition of sodium hydroxide.
The solution was shared at the rate of 150 ml/bottle.
The bottles were stored for 2 years at room temperature. After this period, the titre of NAC resulted to be higher than 95% of the initial one.
Such a titre resulted to be higher than 90% of the initial one also after 5 weeks from the opening of the bottle.
The syrup, also after 2 years of storage, showed to have a pleasant taste and smell and a good general palatability.
Example 2
10 1 of a syrup having the following composition (each 100 ml):
NAC 2.1 g
Sodium saccharin 0.04 g
Hydroxypropyl ethylcellulose 0.2 g
Methyl 4-hydroxybenzoate 0.1 g Sodium edetate 0.1 g
Apricot flavour 0.1 g
Water q.s. to 100 ml were prepared by dispersion of hydroxypropylmethylcellulose in a part of boiling water which was cooled to room temperature. After hydration of hydroxypropylmethylcellulose, it was poured into a solution obtained by dissolving all the remaining substances in purified and de-aerated water, under nitrogen atmosphere.
The pH of the solution was rectified to pH 6.5 with sodium hydroxide.
The solution was shared into single-dose sachets of 10 ml each containing about 200 mg of NAC. Example 3
10 1 of a syrup having the following composition (each 100 ml):
NAC 2.1 g
Sodium saccharin 0.04 g
Hydroxypropylmethylcellulose 0.2 g Sodium edetate 0.1 g
Apricot flavour 0.1 g
Water q.s. to 100 ml were prepared by dispersion of hydroxypropylmethylcellulose in a part of boiling water which was cooled to room temperature. After hydration of hydroxypropylmethylcellulose, it was poured into a solution obtained by dissolving all the remaining substances in purified and de-aerated water, under nitrogen atmosphere.
The pH of the solution was rectified to pH 6.5 with sodium hydroxide. The solution was shared into single-dose glass vials of 10 ml with
rubber stopper each containing about 200 mg of NAC.
Example 4 By working as described in Example 1, 10 1 of syrup having the following composition (each 100 ml) were prepared: NAC 4.2 g
Sodium saccharin 0.08 g
Sodium carboxymethylcellulose 0.20 g Sodium benzoate 0.15 g
Sodium edetate 0.10 g
Raspberry flavour 0.4 g
Water q.s. to 100 ml
The pH of the solution was rectified to pH 6.5 with sodium hydroxide.
The solution was shared into bottles at the rate of 150 ml each bottle.
Example 5 By working as described in Example 2, 10 1 of syrup having the following composition (each 100 ml) were prepared: NAC 2.10 g
Saccharin 0.04 g
Hydroxypropylmethylcellulose 0.40 g Methyl 4-hydroxybenzoate 0.10 g Banana flavour 0.4 g Water q.s. to 100 ml
The pH of the solution was rectified to pH 7 with sodium hydroxide. The solution was shared into bottles at the rate of 450 ml each bottle.
Claims (1)
- Claims1) A composition in the form of a syrup containing (each 100 mi):- N-acetyl-cysteine 2 -4.2 g/100 mi5 - a sweetening agent 0.02-0.3 g/100 mi- a thickening agent selected among: sodium carboxymethylcellulose and hydroxypropylmethylcellulose or mixtures thereof 0.1 -4 g/100 mi10 and optionally:- a flavouring agent 0.1 -0.4 g/100 mi- a preservative 0.05-0.5 g/100 ml and further- water q.s. to 100 ml•5 pH being settled within the interval 5-8.2) A composition according to claim 1 wherein the sweetening agent is selected among saccharin, sodium saccharin, cyclamates or mixtures thereof.3) A composition according to claim 1 wherein the preservative is 0 selected among sodium edetate, sodium benzoate, methyl4-hydroxybenzoate, propyl 4-hydroxybenzoate and mixtures thereof.4) A composition according to claim 1 wherein the pH is between 6.5 and 7.50
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI92002758 | 1992-12-02 | ||
ITMI922758A IT1256616B (en) | 1992-12-02 | 1992-12-02 | SYRUP CONTAINING N-ACETYL-CISTEIN |
PCT/EP1993/003280 WO1994012168A1 (en) | 1992-12-02 | 1993-11-23 | Syrup containing n-acetyl-cysteine |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5626694A AU5626694A (en) | 1994-06-22 |
AU667611B2 true AU667611B2 (en) | 1996-03-28 |
Family
ID=11364395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU56266/94A Expired AU667611B2 (en) | 1992-12-02 | 1993-11-23 | Syrup containing N-acetyl-cysteine |
Country Status (23)
Country | Link |
---|---|
JP (1) | JPH08503703A (en) |
AT (1) | AT407113B (en) |
AU (1) | AU667611B2 (en) |
BE (1) | BE1006799A3 (en) |
CA (1) | CA2150462C (en) |
CH (1) | CH685371A5 (en) |
CZ (1) | CZ282550B6 (en) |
DE (2) | DE4396086T1 (en) |
DK (1) | DK176247B1 (en) |
ES (1) | ES2070806B1 (en) |
FR (1) | FR2698545B1 (en) |
GB (1) | GB2288977B (en) |
HU (2) | HU221484B (en) |
IT (1) | IT1256616B (en) |
LU (1) | LU88618A1 (en) |
MD (1) | MD1714G2 (en) |
NL (1) | NL194957C (en) |
NO (1) | NO314018B1 (en) |
NZ (1) | NZ258544A (en) |
RU (1) | RU2108777C1 (en) |
SE (1) | SE520834C2 (en) |
UA (1) | UA27142C2 (en) |
WO (1) | WO1994012168A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT766557E (en) * | 1994-06-23 | 2002-05-31 | Procter & Gamble | APPLICATION COMPOSITIONS TOPIC COMPREHENDING N-ACETYL-CYSTEIN |
JP4501023B2 (en) * | 2002-11-14 | 2010-07-14 | 小林製薬株式会社 | Composition with reduced bitterness and odor of cysteines |
JP4501024B2 (en) * | 2002-11-14 | 2010-07-14 | 小林製薬株式会社 | Composition with reduced bitterness and odor of cysteines |
US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
CN102233139B (en) * | 2010-04-21 | 2012-09-05 | 重庆健能医药开发有限公司 | Acetylcysteine effervescent tablet and preparation method and application thereof |
RU2611411C1 (en) * | 2016-01-11 | 2017-02-21 | Общество с ограниченной ответственностью "Трейдсервис" | Dispersible in water acetylcysteine tablet and method of manufacturing thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2192789A (en) * | 1986-07-24 | 1988-01-27 | Inpharzam Int Sa | Acetylcysteine compositions |
FR2631831A1 (en) * | 1988-05-31 | 1989-12-01 | Calco Anstalt | Syrups based on xylitol, ribitol or arabitol |
EP0481294A1 (en) * | 1990-10-19 | 1992-04-22 | Spirig Ag Pharmazeutische Präparate | Solid fast-dissolving pharmaceutical preparation containing S-(carboxymethyl)-L-cysteine and/or N-acetyl-cysteine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB905197A (en) * | 1960-01-01 | 1962-09-05 | Lab Francais Chimiotherapie | Anti-viral compositions comprising 1-phenyl-2-amino-propane-1,3-diol derivatives |
CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
BE901885A (en) * | 1985-03-06 | 1985-07-01 | Bruschettini Srl | Stable ophthalmic soln. contg. N-acetyl-cysteine - prepd. in nitrogen satd. aq. buffer free of metal ions |
CH667590A5 (en) * | 1986-07-24 | 1988-10-31 | Inpharzam Int Sa | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . |
US4861797A (en) * | 1987-10-15 | 1989-08-29 | Oratech Pharmaceutical Development Corporation | Liquid ibuprofen compositions and methods of making them |
CH674940A5 (en) * | 1988-05-05 | 1990-08-15 | Ibsa Inst Biochimique Sa | |
ATE87476T1 (en) * | 1988-11-10 | 1993-04-15 | Ciba Geigy Ag | LIQUID ORAL FORMULATION. |
IT1231012B (en) * | 1989-07-27 | 1991-11-08 | Zambon Spa | PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING NAC. |
IT1248998B (en) * | 1990-06-26 | 1995-02-11 | Iscofar Sas | COMPOSITION OF RUBBER TO BE CHEWED FOR THE PREVENTION AND TREATMENT OF DENTAL PLATE |
-
1992
- 1992-12-02 IT ITMI922758A patent/IT1256616B/en active IP Right Grant
-
1993
- 1993-11-23 DE DE4396086T patent/DE4396086T1/en active Pending
- 1993-11-23 HU HU9501586A patent/HU221484B/en unknown
- 1993-11-23 AT AT0906093A patent/AT407113B/en not_active IP Right Cessation
- 1993-11-23 CH CH2423/94A patent/CH685371A5/en not_active IP Right Cessation
- 1993-11-23 GB GB9509822A patent/GB2288977B/en not_active Expired - Lifetime
- 1993-11-23 NL NL9320052A patent/NL194957C/en not_active IP Right Cessation
- 1993-11-23 CA CA002150462A patent/CA2150462C/en not_active Expired - Lifetime
- 1993-11-23 NZ NZ258544A patent/NZ258544A/en not_active IP Right Cessation
- 1993-11-23 WO PCT/EP1993/003280 patent/WO1994012168A1/en active IP Right Grant
- 1993-11-23 ES ES09450021A patent/ES2070806B1/en not_active Expired - Fee Related
- 1993-11-23 CZ CZ951367A patent/CZ282550B6/en not_active IP Right Cessation
- 1993-11-23 MD MD96-0265A patent/MD1714G2/en unknown
- 1993-11-23 DE DE4396086A patent/DE4396086B3/en not_active Expired - Lifetime
- 1993-11-23 JP JP6512747A patent/JPH08503703A/en active Pending
- 1993-11-23 RU RU95114406A patent/RU2108777C1/en active
- 1993-11-23 UA UA95062994A patent/UA27142C2/en unknown
- 1993-11-23 AU AU56266/94A patent/AU667611B2/en not_active Expired
- 1993-12-01 BE BE9301326A patent/BE1006799A3/en not_active IP Right Cessation
- 1993-12-02 FR FR9314443A patent/FR2698545B1/en not_active Expired - Lifetime
-
1994
- 1994-05-24 LU LU88618A patent/LU88618A1/en unknown
-
1995
- 1995-05-31 DK DK199500614A patent/DK176247B1/en not_active IP Right Cessation
- 1995-06-01 SE SE9502001A patent/SE520834C2/en not_active IP Right Cessation
- 1995-06-01 NO NO19952183A patent/NO314018B1/en not_active IP Right Cessation
- 1995-06-29 HU HU95P/P00579P patent/HU211912A9/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2192789A (en) * | 1986-07-24 | 1988-01-27 | Inpharzam Int Sa | Acetylcysteine compositions |
FR2631831A1 (en) * | 1988-05-31 | 1989-12-01 | Calco Anstalt | Syrups based on xylitol, ribitol or arabitol |
EP0481294A1 (en) * | 1990-10-19 | 1992-04-22 | Spirig Ag Pharmazeutische Präparate | Solid fast-dissolving pharmaceutical preparation containing S-(carboxymethyl)-L-cysteine and/or N-acetyl-cysteine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0431663B1 (en) | Stabilized solutions of psychotropic agents | |
CA2121435C (en) | Aqueous pharmaceutical suspension and process for preparation thereof | |
CZ114093A3 (en) | Sulfate of 3-£2-(dimethylamino)ethyl-n-methyl-1h-indole-5-methane sulfonamide, and pharmaceutical preparations containing thereof | |
ES2210121T3 (en) | STABLE PHARMACEUTICAL PREPARATION, WHICH CAN BE USED BY NASAL, ORAL OR SUBLINGUAL VIA CONTAINING DESMOPRESIN. | |
AU667611B2 (en) | Syrup containing N-acetyl-cysteine | |
US5807894A (en) | Syrup containing N-acetyl-cysteine | |
PT1747781E (en) | Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients | |
US20230301945A1 (en) | Stable pharmaceutical compositions of hydroxyurea | |
JPS5914447B2 (en) | pH and Color Stabilized Aqueous Antibiotic Compositions for Parenteral Administration | |
KR20050034619A (en) | New dry and aqueous epinastine-syrup-formulation | |
KR100254107B1 (en) | Stable liquid preparation of complex vitamin for internal use | |
US3109773A (en) | Bronchodilator expectorant composition containing theophylline and a guaiacol | |
CZ243898A3 (en) | Aqueous formulation of bambuterol and application thereof | |
JPH08337522A (en) | Aqueous liquid preparation of ambroxole hydrochloride | |
CA2120751C (en) | Trimethoprim oral liquid | |
USRE29359E (en) | Bronchodilator expectorant composition containing theophylline and a guaiacol | |
US20030104017A1 (en) | Epinastine formulation for oral administration | |
JP2000204036A (en) | Glutamic salt-containing liquid preparation | |
KR100718211B1 (en) | Tixocortol Pivalate Suspension, Mouth-Wash Based Thereon and Packaging Containing Same | |
JPH085784B2 (en) | Syrup | |
JPH11139970A (en) | Oral solution | |
NL193607C (en) | Pharmaceutical preparation containing N-acetylcysteine. | |
JPH0819000B2 (en) | Syrup | |
MXPA00005129A (en) | Liquid and stable antihistaminic - anti-congestive pharmaceutical compositions | |
ES2684594A1 (en) | Aqueous solution of ranitidine free of ethanol (Machine-translation by Google Translate, not legally binding) |